FDA.reportPublic FDA data

tocilizumab-anoh 80 MG per 4 ML Injection

RxCUI
2705452
RxNorm name
tocilizumab-anoh 80 MG per 4 ML Injection
Display name
tocilizumab-anoh 80 MG per 4 ML Injection
Full name
tocilizumab-anoh 80 MG per 4 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:00

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761420Avtozmatocilizumab-anoh351(k) InterchangeableRx2026-09-01
761498Avtozmatocilizumab-anoh351(k) InterchangeableRx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
581c288f-8015-40ef-a4c3-683c96db193dtocilizumab-anoh 80 MG in 4 ML Injection [PSN] · 4 ML tocilizumab-anoh 20 MG/ML Injection [SCD] · tocilizumab-anoh 20 MG/ML per 4 ML Injection [SY] · tocilizumab-anoh 80 MG per 4 ML Injection [SY]44These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123
60381a7e-d7ae-4384-925d-c19c418d1663tocilizumab-anoh 80 MG in 4 ML Injection [PSN] · 4 ML tocilizumab-anoh 20 MG/ML Injection [SCD] · tocilizumab-anoh 20 MG/ML per 4 ML Injection [SY] · tocilizumab-anoh 80 MG per 4 ML Injection [SY]44These highlights do not include all the information needed to use TOCILIZUMAB-ANOH safely and effectively. See full prescribing information for TOCILIZUMAB-ANOH. TOCILIZUMAB-ANOH injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 Tocilizumab-anoh is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif20260123